Roche’s experimental obesity drug shows strong weight-loss results in mid-stage trial

The company announced positive topline data from the Phase II ZUPREME-1 trial

Roche’s Gazyva shows breakthrough results in Lupus phase III trial

Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints

Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026

The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations

Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial

Merck emphasized the broader significance of the findings

Bioxytran reports 90% day-5 viral clearance in COVID-19 trial at highest dose of ProLectin-M

Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile

Iza-bren delivers dual survival win in phase III trial for hard-to-treat breast cancer

Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival

IRLAB Therapeutics doses first patient in pivotal apathy trial

The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain

Zydus hits Keytruda biosimilar milestone with successful FYB206 trial, targets USFDA filing

Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets

Pfizer and Astellas report groundbreaking results in muscle-invasive bladder cancer trial

Eli Lilly’s orforglipron outshines oral semaglutide in landmark diabetes trial

The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints